Literature DB >> 17178304

The Paul Coverdell National Acute Stroke Registry: initial results from four prototypes.

Mathew J Reeves1, Joseph P Broderick, Michael Frankel, Kenneth A LaBresh, Lee Schwamm, Charles J Moomaw, Paul Weiss, Irene Katzan, Shalini Arora, John P Heinrich, Susan Hickenbottom, Herbert Karp, Ann Malarcher, George Mensah, Mathew J Reeves1.   

Abstract

BACKGROUND: This paper summarizes the experiences of the Paul Coverdell National Acute Stroke Registry first four prototype registries in Georgia (GA), Massachusetts (MA), Michigan (MI), and Ohio (OH), and includes information on their sampling design, case ascertainment, and data collection methods, as well as some key findings.
METHODS: Using a combination of different sampling methods, each prototype obtained a representative statewide sample of hospitals. Acute stroke admissions were identified through prospective (MA, MI) or retrospective (GA, OH) methods. A common set of case definitions and data elements were used by each registry. Weighted site-specific frequencies and 95% confidence intervals were generated for each outcome. A summary estimate, representing a weighted average of the four site-specific estimates, was also calculated.
RESULTS: Of the total 6867 admissions, 1487 (21.6%) were from the GA registry, 1206 (17.6%) from MA, 2566 (37.4%) from MI, and 1608 (23.4%) from the OH prototype. Just less than 60% of admissions were ischemic strokes (site-specific estimates ranged from 52% to 70%), with transient ischemic attack (18.5%) and intracerebral hemorrhage (8.8%) making up most of the remainder. Twenty-one percent of patients admitted were younger than 60 years of age, and 55.3% were women. The proportion of black subjects varied from 7.1% (MI) to 30.6% (GA). Twenty-three percent of admissions arrived at the emergency department within 3 hours of onset. Overall 4.5% of ischemic stroke admissions were treated with recombinant tissue plasminogen activator; site-specific treatment rates were 3.0% (GA), 3.2% (OH), 3.4% (MI), and 8.5% (MA). Only a small minority of treated patients (range, 10.8% [OH] to 19.6% [MI]) received recombinant tissue plasminogen activator within the recommended 1 hour door-to-needle time. A minority of eligible subjects were screened for dysphagia (45.4%), underwent lipid testing (33.6%), or received smoking-cessation counseling (21.4%). In contrast, compliance with antithrombotic treatments at discharge was high (91.5%).
CONCLUSIONS: A minority of acute stroke patients are treated according to established guidelines. Quality improvement interventions, targeted primarily at the healthcare systems level, are needed to improve acute stroke care in the United States.

Entities:  

Mesh:

Year:  2006        PMID: 17178304     DOI: 10.1016/j.amepre.2006.08.007

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  10 in total

1.  Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion.

Authors:  Alexander Kunz; Takato Abe; Karin Hochrainer; Munehisa Shimamura; Josef Anrather; Gianfranco Racchumi; Ping Zhou; Costantino Iadecola
Journal:  J Neurosci       Date:  2008-02-13       Impact factor: 6.167

2.  Prehospital notification by emergency medical services reduces delays in stroke evaluation: findings from the North Carolina stroke care collaborative.

Authors:  Mehul D Patel; Kathryn M Rose; Emily C O'Brien; Wayne D Rosamond
Journal:  Stroke       Date:  2011-06-09       Impact factor: 7.914

Review 3.  Intracerebral hemorrhage specific intensity of care quality metrics.

Authors:  Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

4.  Impact of a multimedia campaign to increase intention to call 9-1-1 for stroke symptoms, upstate New York, 2006-2007.

Authors:  Janine M Jurkowski; Dayna M Maniccia; Deborah A Spicer; Barbara A Dennison
Journal:  Prev Chronic Dis       Date:  2010-02-15       Impact factor: 2.830

5.  The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic.

Authors:  Takato Abe; Alexander Kunz; Munehisa Shimamura; Ping Zhou; Josef Anrather; Costantino Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-23       Impact factor: 6.200

Review 6.  Edaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Naoki Miura; Ko-Ichi Kawahara; Yoshinaka Murai; Motohiro Morioka; Paul A Lapchak; Eiichiro Tanaka
Journal:  Biomed Rep       Date:  2012-08-29

7.  Temporal Changes in the Quality of Acute Stroke Care in Five National Audits across Europe.

Authors:  Steffi Hillmann; Silke Wiedmann; Alec Fraser; Juan Baeza; Anthony Rudd; Bo Norrving; Kjell Asplund; Maciej Niewada; Martin Dennis; Peter Hermanek; Charles D A Wolfe; Peter U Heuschmann
Journal:  Biomed Res Int       Date:  2015-12-09       Impact factor: 3.411

8.  The Karachi intracranial stenosis study (KISS) Protocol: an urban multicenter case-control investigation reporting the clinical, radiologic and biochemical associations of intracranial stenosis in Pakistan.

Authors:  Ayeesha Kamran Kamal; Fawad Taj; Babar Junaidi; Asif Rasheed; Moazzam Zaidi; Muhammed Murtaza; Naved Iqbal; Fahad Hashmat; Syed Vaqas Alam; Uzma Saleem; Shahan Waheed; Lajpat Bansari; Nabi Shah; Maria Samuel; Madiha Yameen; Sobia Naz; Farrukh Shahab Khan; Naveeduddin Ahmed; Khalid Mahmood; Niaz Sheikh; Karim Ullah Makki; Muhammad Masroor Ahmed; Abdul Rauf Memon; Mohammad Wasay; Nadir Ali Syed; Bhojo Khealani; Philippe M Frossard; Danish Saleheen
Journal:  BMC Neurol       Date:  2009-07-15       Impact factor: 2.474

Review 9.  Delayed Recanalization-How Late Is Not Too Late?

Authors:  Ruiqing Kang; Marcin Gamdzyk; Hong Tang; Yujie Luo; Cameron Lenahan; John H Zhang
Journal:  Transl Stroke Res       Date:  2020-11-20       Impact factor: 6.800

10.  The role of public health in promoting quality improvement in care for stroke and heart disease.

Authors:  Mary G George; Michael D Matters; Henraya F McGruder; Amy L Valderrama; Jipan Xie
Journal:  Prev Chronic Dis       Date:  2008-03-15       Impact factor: 2.830

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.